On November 2, the Indian Intellectual Property Appellate Board (IPAB) revoked Hoffmann-La Roche’s patent on the hepatitis C drug Pegasys. In particular, the IPAB found that Roche failed to demonstrate Pegasys is more efficacious than an earlier version of the drug. Read the ruling here. The ruling brings three critical issues to the fore. The … Continue reading Guest column : What Pegasys says about IPR in India
I'd like to introduce a guest column by Salil Kallianpur, a healthcare marketing professional with experience in the pharmaceutical and medical devices industries. Salil is an avid reader and follower of healthcare current affairs, its politics, and strategies. He comments on the intersection of healthcare and life on his blog My Pharma Reviews. He is … Continue reading Think different : Big Pharma and drug pricing in emerging markets
My colleague Vikas Dandekar of Pharmasianews reports on a potentially pathbreaking event. Swiss drug maker Roche has struck a manufacturing deal with Pune's Emcure to produce some portion of its blockbuster biologic Herceptin for breast cancer and Pegasys for hepatitis B and C in India for India. Of course, it doesn't look as if Emcure … Continue reading Roche’s Emcure deal – thumbs up for market economics?